Prescription Required
Canmab 440mg Injection 1s is a targeted therapy used primarily in the treatment of HER2-positive breast and stomach cancers. Manufactured by Biocon, it contains the active ingredient Trastuzumab, a monoclonal antibody designed to interfere with the HER2/neu receptor. Overexpression of this receptor is associated with aggressive tumor growth. By targeting HER2, Canmab helps inhibit the proliferation of cancer cells.
Canmab 440mg Injection may cause excessive drowsiness with alcohol.
Canmab 440mg Injection is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Canmab 440mg Injection is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
It is not known whether Canmab 440mg Injection alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Canmab 440mg Injection is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Canmab 440mg Injection may not be needed in these patients. Please consult your doctor.
There is limited information available on the use of Canmab 440mg Injection in patients with liver disease. Please consult your doctor.
Trastuzumab, the active component of Canmab, binds specifically to the HER2 receptors on the surface of cancer cells. This binding blocks the receptors, preventing them from receiving growth signals. Additionally, Trastuzumab flags these cells for destruction by the body's immune system, enhancing the anti-tumor response. This dual action not only inhibits tumor growth but also promotes the elimination of cancer cells.
HER2-positive cancers overexpress the human epidermal growth factor receptor 2 (HER2), leading to rapid and uncontrolled cell growth. This subtype is more aggressive but responds well to therapies like Trastuzumab that specifically target the HER2 receptor.
Content Updated on
Saturday, 12 April, 2025Prescription Required
Simplify your healthcare journey with Indian Government's ABHA card. Get your card today!
Create ABHA